Clinical Trial Designs

Navigating the Maze of Adaptive Design Clinical Trials

Unfavorable results during the clinical phase studies will put a damper on the drug’s journey to market. Traditionally, pharmaceutical manufacturers should have a clear hypothesis and realistic endpoints of the trial. An adaptive design clinical trials allows more flexibility in clinical studies by allowing modifications to the trial. The modifications can be done after the trial…

Shifting from a One Drug Paradigm

Shifting from a One Drug Paradigm

A one-size-fits-all approach to drug therapy can be rather ineffective when treating today’s diseases. Pharmaceutical companies understand treating complex diseases such as cancer or HIV will require an effective combination of drug therapies. Combination drug product development offers significant therapeutic impact. Modern pharmacology recognizes that diseases are often multifactorial, consisting of a spectrum of medical…

Monograph and NDA Pathways for OTC Drugs

Monograph and NDA Pathways for OTC Drugs

Over-the-counter (OTC) drug products are a billion-dollar industry consisting of over one hundred thousand OTC drugs marketed currently. OTC drugs also known as nonprescription drugs are not held in the same class as prescription drugs since they do not have high toxicity requiring practitioner supervision. Similar to prescription drugs, there are FDA drug labeling requirements…

The FDA Drug Approval Process Improved

The FDA Drug Approval Process Improved

In 2018, the FDA pledged to improve the drug approval process and the efficiency of drug development, allowing pharmaceutical development consulting firms to serve their clients more effectively. In attempt to prevent drug shortages and to increase generic drug access, the FDA is improving their drug review process. Pharmaceutical development services can be expedited due…

Regulatory Consulting- the Missing Piece to Your Puzzle

Regulatory Consulting- the Missing Piece to Your Puzzle

A trend of outsourcing regulatory affairs services has increased considerably. A lack of talented regulatory affairs professionals and stringent FDA regulations has contributed to the rising need for experienced FDA regulatory consultants. Pharmaceutical and device developers are focusing their energy in research and development operations while partnering with FDA regulatory consultants to provide regulatory affairs…

Trump Budget Headlines Include Generic Exclusivity Changes; Medicare/Medicaid Savings

On February 8, 2018, Bloomberg Politics reported HHS Secretary Alex Azar’s announcement that “…he plans to take up the president’s promises to do something about pharmaceutical prices, targeting some of the U.S.’s costliest drugs with proposals to reduce patients’ out-of-pocket spending. ‘The president is firmly committed in this space,’ Health and Human Services Secretary Alex…